EUVIMEDEUVIMED entdecken
Übersichtsarbeit

From Neoantigen Discovery to Immune‐Checkpoint Synergy: Peptide Cancer Vaccines as Precision Tools for Personalised Cancer Therapy

Abid H Banday, Meer Mehru Manzoor, Urooj Nissar, Seeham Jaleel

Scandinavian Journal of Immunology · 2026-01 · 103 (1)

DOI: 10.1111/sji.70084 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Scandinavian Journal of Immunology, online erschienen am 11.01.2026. Verfasst von Abid H Banday und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Islamia College of Science and Commerce, Srinagar, India. Hauptthemen laut MEDLINE: Cancer Vaccines, Antigens, Neoplasm, Precision Medicine, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 166 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The diagnosis, management and potential eradication of cancer depend on tumour type, stage, extent and anatomical location. While surgery, chemotherapy and radiotherapy remain central, advances in molecular oncology have shifted treatment toward personalised approaches. Identification of tumour‐specific molecular abnormalities and biomarkers has enabled targeted therapies that eliminate malignant cells while limiting damage to normal tissues. Cancer immunotherapy has emerged as a promising, non‐invasive strategy that activates the immune system to recognise and attack tumour‐specific antigens. Preventive vaccines based on weakened or inactivated viruses have achieved notable success in reducing virus‐associated cancers. Therapeutic vaccines targeting tumour‐associated antigens (TAAs) and patient‐specific neoantigens aim to elicit strong cytotoxic and helper T‐cell responses against established tumours. Advances in genomic sequencing, bioinformatics‐driven neoantigen prediction and single‐cell profiling now enable accurate identification of tumour‐specific targets. This review highlights progress in cancer vaccine research, focusing on strategies targeting TAAs, neoantigens and delivery platforms such as dendritic cell–based systems, nucleic acid vaccines (DNA and mRNA), synthetic long peptides and viral or bacterial vectors. Clinical evidence shows that neoantigen vaccines induce potent tumour‐specific T‐cell responses with minimal autoimmunity and gain enhanced efficacy when combined with immune checkpoint inhibitors or adoptive T‐cell transfer (ACT) using tumour‐infiltrating lymphocytes (TILs). By reinvigorating anti‐tumour T cells within the tumour microenvironment, these combination approaches support durable tumour regression and improved outcomes. Despite unresolved challenges, advances in AI‐guided target discovery, nanotechnology‐based delivery systems and scalable manufacturing offer promising solutions for achieving precise and durable cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesAntigens, NeoplasmPrecision MedicineNeoplasmsImmunotherapyHumansProtein Subunit VaccinesAnimalsImmune Checkpoint InhibitorsVaccines, SubunitDendritic Cells

Stichwörter der Autor:innen

cancer immunotherapycombination therapyimmune‐checkpoint synergyneoantigen vaccinespersonalised cancer vaccines

Substanzen

Cancer VaccinesAntigens, NeoplasmProtein Subunit VaccinesImmune Checkpoint InhibitorsVaccines, Subunit

Autor:innen und Institutionen

  • Department of Chemistry, Islamia College of Science and Commerce, Srinagar, India.
  • Department of Chemistry and Biochemistry, Auburn University, Auburn, Alabama, USA.
  • School of Sciences, Department of Chemistry, Cluster University of Jammu, Jammu-Tawi, India.
  • Government Medical College Baramulla, Baramulla, Jammu and Kashmir, India.

Zitieren

APA

Banday, A. H., Manzoor, M. M., Nissar, U., & Jaleel, S. (2026). From Neoantigen Discovery to Immune‐Checkpoint Synergy: Peptide Cancer Vaccines as Precision Tools for Personalised Cancer Therapy. Scandinavian Journal of Immunology, 103(1). https://doi.org/10.1111/sji.70084

Vancouver

Banday AH, Manzoor MM, Nissar U, Jaleel S. From Neoantigen Discovery to Immune‐Checkpoint Synergy: Peptide Cancer Vaccines as Precision Tools for Personalised Cancer Therapy. Scandinavian Journal of Immunology. 2026;103(1). doi:10.1111/sji.70084

BibTeX
@article{Banday2026,
  author = {Banday, Abid H and Manzoor, Meer Mehru and Nissar, Urooj and Jaleel, Seeham},
  title = {From Neoantigen Discovery to Immune‐Checkpoint Synergy: Peptide Cancer Vaccines as Precision Tools for Personalised Cancer Therapy},
  journal = {Scandinavian Journal of Immunology},
  year = {2026},
  volume = {103},
  number = {1},
  doi = {10.1111/sji.70084}
}
Kostenlos starten →